Squarepoint Ops LLC Cidara Therapeutics, Inc. Transaction History

Squarepoint Ops LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$1.18 - $2.18 $103,154 - $190,573	-87,419 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$1.48 - $2.35 $45,973 - $72,998	-31,063 Reduced 26.22%	87,419 $196,000
Q2 2021 Aug 16, 2021	SELL	$1.87 - $2.7 $128,446 - $185,457	-68,688 Reduced 36.7%	118,482 $239,000
Q1 2021 May 17, 2021	BUY	$2.06 - $3.01 $192,012 - $280,562	93,210 Added 99.2%	187,170 $498,000
Q4 2020 Feb 16, 2021	BUY	$1.99 - $3.25 $48,723 - $79,573	24,484 Added 35.24%	93,960 $188,000

Q3 2020 Nov 16, 2020	SELL	$2.85 - $4.1 $56,313 - $81,011	-19,759 Reduced 22.14%	69,476 $198,000
Q2 2020 Aug 14, 2020	BUY	$2.39 - $4.0 $187,631 - $314,028	78,507 Added 731.8%	89,235 $329,000
Q1 2020 May 15, 2020	BUY	$1.74 - $4.26 $18,666 - $45,701	10,728 New	10,728 $27,000
Q4 2017 Feb 14, 2018	SELL	$6.35 - $8.75 $130,809 - $180,250	-20,600 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$5.75 - $8.1 $118,450 - $166,860	20,600	20,600 $167,000

22.1M

2.7K

100

Ticker CDTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,075,696
Market Cap $889M
Description
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifu...

Get notified when there are updates to the investment portfolio of Squarepoint Ops LLC, based on Form 13F filings with the SEC.

Stay updated on Squarepoint Ops LLC with notifications on news.